Medipal Holdings (MAHLY) Fair Value & Analysis
Healthcare · US · Market cap $3.2B
Medipal Holdings
MAHLY · US
Fair value as of: Jul 18, 2026
From 25 valuation models · updated 7 days ago
Fair value updated Jul 18, 2026, revised from $31.00 to $30.05 (−3.1%) since Jun 24, 2026. Share price +14.7% over the past month.
Price vs Fair Value (12 months)
12‑month range $13.56 – $19.30 · fair‑value band $22.54 – $37.57 · the $17.63 price screens below the $30.05 fair value. As of Jul 18, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Medipal Holdings (MAHLY) currently trades at $17.63, while our model-based Fair Value estimate is $30.05, implying the stock looks roughly 70.5% undervalued today. We read business quality at 61/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, Medipal Holdings generated revenue of $3.8T at a net margin of 1.1%. Revenue grew 4.8% year over year. It earns a return on equity of 6.8%. The balance sheet holds a net cash position of $290B. Fundamentals as of Jul 18, 2026
Our scenario range runs from $22.54 (bear case) to $37.57 (bull case); at $17.63, the current price sits below that range. The share trades about 9% below its 52-week high and 13% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -30% fair-value upside, at 70%, MAHLY screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 18, 2026. TTM = trailing twelve months.
About the company
Medipal Holdings Corporation engages in the prescription pharmaceutical wholesale business in Japan. It procures healthcare products related to diagnostics, testing, treatment, and administration comprising medical equipment and medical materials, and clinical diagnostic reagents for use from the pre-symptomatic stage; handles PMS services on contract for manufacturers; and invests in orphan drugs and other products. The company is also involved in the wholesale of cosmetics, daily necessities, and OTC pharmaceuticals; and animal health products for companion animals; and food processing raw materials for agriculture, fisheries, and livestock. In addition, it engages in the contract-based epidemiological studies, clinical studies, etc.; creation of a computerized medical supply database and master product databases for medical facilities; life and non-life insurance agency business; cleaning management; management and operation of distribution centers; commissioned delivery and …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Medipal Holdings reported revenue of $4.0T in FY2026 versus $3.3T in FY2022, a compound +5.3%/yr. Reported net income was $45.1B in FY2026, compounding +11.3%/yr from FY2022.
Is MAHLY fairly valued? → Check now
Similar stocks
10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Jul 18, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| McKesson Corporation M1CK34 | R$958.36 | R$188.90 | -80% |
| Cencora, Inc COR | $271.28 | $175.74 | -35% |
| Cardinal Health, Inc CAH | $222.74 | $141.77 | -36% |
| Sigma Healthcare Limited SIGGF | $2.35 | $0.6300 | -73% |
| Henry Schein, Inc HSIC | $76.30 | $53.31 | -30% |
| Shanghai Pharmaceuticals Holding 601607 | ¥15.96 | ¥45.15 | +183% |
| Galenica AG GALNF | $115.00 | $98.28 | -15% |
| Guangzhou Baiyunshan Pharmaceutical Holdings 600332 | ¥21.69 | ¥25.18 | +16% |
| Jointown Pharmaceutical Group 600998 | ¥4.87 | ¥9.24 | +90% |
| Amplifon S.p.A AMP | €10.46 | €5.72 | -45% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Medipal Holdings (MAHLY) undervalued?
What is the fair value of MAHLY?
What is the quality score of MAHLY?
What is the revenue of Medipal Holdings (MAHLY)?
What is the net profit margin of MAHLY?
Does Medipal Holdings pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Medipal Holdings analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.